Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Tomas Buchler, Renata Chloupkova, Alexandr Poprach, Ondrej Fiala, Igor Kiss, Katerina Kopeckova, Ladislav Dusek, Veronika Veskrnova, Lubomir Slavicek, Milan Kohoutek, Jindrich Finek, Marek Svoboda, Lubos Petruzelka & Bohuslav Melichar. (2019) Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis. Cancer Management and Research 11, pages 359-368.
Read now
Read now
Articles from other publishers (17)
Guoqing Diao, Haijun Ma, Donglin Zeng, Chunlei Ke & Joseph G. Ibrahim. (2022) Synthesizing studies for comparing different treatment sequences in clinical trials. Statistics in Medicine 41:25, pages 5134-5149.
Crossref
Crossref
Eleonora Lai, Stefano Cascinu & Mario Scartozzi. (2021) Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. Frontiers in Oncology 11.
Crossref
Crossref
R. Vera, M. Salgado, M. J. Safont, J. Gallego, E. González, E. Élez & E. Aranda. (2020) Controversies in the treatment of RAS wild-type metastatic colorectal cancer. Clinical and Translational Oncology 23:4, pages 827-839.
Crossref
Crossref
Ji Yan, Shida Yang, Hong Tian, Yang Zhang & Hongmei Zhao. (2020) Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer. Cell Death & Disease 11:11.
Crossref
Crossref
Jean Marc Phelip, David Tougeron, David Léonard, Leonor Benhaim, Grégoire Desolneux, Aurélien Dupré, Pierre Michel, Christophe Penna, Christophe Tournigand, Christophe Louvet, Nikki Christou, Patrick Chevallier, Anthony Dohan, Benoist Rousseaux & Olivier Bouché. (2019) Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Digestive and Liver Disease 51:10, pages 1357-1363.
Crossref
Crossref
Hung‐Chih Hsu, Yu‐Chun Liu, Chuang‐Wei Wang, Wen-Chi Chou, Yu-Jen Hsu, Jy-Ming Chiang, Yung-Chang Lin & Tsai-Sheng Yang. (2019) Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer. Cancer Medicine 8:7, pages 3437-3446.
Crossref
Crossref
Hiroya Taniguchi, Yuji Baba, Yoji Sagiya, Masamitsu Gotou, Kazuhide Nakamura, Hiroshi Sawada, Kazunori Yamanaka, Yukiko Sakakibara, Ikuo Mori, Yukiko Hikichi, Junpei Soeda & Hideo Baba. (2018) Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab. Neoplasia 20:7, pages 668-677.
Crossref
Crossref
Julian Walter Holch, Ingrid Ricard, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Frank Kullmann, Werner Scheithauer, Michael Scholz, Sebastian Müller, Hartmut Link, Andreas Rost, Heinz‐Gert Höffkes, Markus Moehler, Reinhard Udo Lindig, Lisa Miller‐Phillips, Thomas Kirchner, Andreas Jung, Jobst Christian von Einem, Dominik Paul Modest & Volker Heinemann. (2017) Relevance of liver‐limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE‐3/AIO KRK0306 trial. International Journal of Cancer 142:5, pages 1047-1055.
Crossref
Crossref
Marc Peeters, Frédéric Forget, Meinolf Karthaus, Manuel Valladares-Ayerbes, Alberto Zaniboni, Gaston Demonty, Xuesong Guan & Fernando Rivera. (2018) Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma. ESMO Open 3:2, pages e000297.
Crossref
Crossref
Fernando Rivera, Meinolf Karthaus, J. Randolph Hecht, Isabel Sevilla, Frédéric Forget, Gianpiero Fasola, Jean-Luc Canon, Xuesong Guan, Gaston Demonty & Lee S. Schwartzberg. (2017) Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. International Journal of Colorectal Disease 32:8, pages 1179-1190.
Crossref
Crossref
Xinli Huang & Sen Lu. (2017) MicroR-545 mediates colorectal cancer cells proliferation through up-regulating epidermal growth factor receptor expression in HOTAIR long non-coding RNA dependent. Molecular and Cellular Biochemistry 431:1-2, pages 45-54.
Crossref
Crossref
Athanassios Argiris, Kevin J. Harrington, Makoto Tahara, Jeltje Schulten, Pauline Chomette, Ana Ferreira Castro & Lisa Licitra. (2017) Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Frontiers in Oncology 7.
Crossref
Crossref
Dominik P. Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Werner Scheithauer, Thomas Kirchner, Andreas Jung, Martina Stauch, Jobst Christian von Einem, Markus Moehler, Swantje Held & Volker Heinemann. (2017) Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306). International Journal of Cancer 140:8, pages 1918-1925.
Crossref
Crossref
Volker Heinemann & Sebastian Stintzing. 2017. Immunotherapy for Gastrointestinal Cancer. Immunotherapy for Gastrointestinal Cancer
217
244
.
Long Bai, Feng Wang, Zhe-zhen Li, Chao Ren, Dong-sheng Zhang, Qi Zhao, Yun-xin Lu, De-shen Wang, Huai-qiang Ju, Miao-zhen Qiu, Zhi-qiang Wang, Feng-hua Wang & Rui-hua Xu. (2016) Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer. Medicine 95:51, pages e4531.
Crossref
Crossref
Volker Heinemann, Fernando Rivera, Bert H. O'Neil, Sebastian Stintzing, Reija Koukakis, Jan-Henrik Terwey & Jean-Yves Douillard. (2016) A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. European Journal of Cancer 67, pages 11-20.
Crossref
Crossref
Hong Chen, Jingjing Wang, Hong Yang, Dan Chen & Panpan Li. (2016) Association between FOXM1 and hedgehog signaling pathway in human cervical carcinoma by tissue microarray analysis. Oncology Letters 12:4, pages 2664-2673.
Crossref
Crossref